Individual treatment with ABT-199 and A-1210477 caused increased levels of Mcl-1 without changing the levels of Bcl-2, Bim, and Bcl-xL in THP-1, U937, and a primary AML patient sample derived at relapse (Figures 2a–c). Here, BCL2 is linked to acute myeloid leukemia.